This sustained immune activation elicited by combination therapy was further supported by functional analysis demonstrating a significant increase in activated bifunctional CD8+ T cells producing both IFNγ and TNFα at day 25 (Fig. 4e), which also correlated with tumor size reduction (Fig. 4f). Here, CD8A is linked to neoplasm.